Targeting Adaptive Pathways in Metastatic Treatment-Resistant Prostate Cancer: Update on the Stand Up 2 Cancer/Prostate Cancer Foundation-Supported West Coast Prostate Cancer Dream Team.
Publication
, Journal Article
Aggarwal, R; Beer, TM; Gleave, M; Stuart, JM; Rettig, M; Evans, CP; Youngren, J; Alumkal, JJ; Huang, J; Thomas, G; Witte, O; Small, EJ
Published in: Eur Urol Focus
December 2016
The Stand Up 2 Cancer/Prostate Cancer Foundation-funded West Coast Dream Team project is a prospective multi-institutional study focused on acquiring metastatic castration-resistant prostate cancer (mCRPC) biopsy tissue at the time of resistance to abiraterone or enzalutamide. It is the first large-scale study designed to analyze mCRPC tissue specifically in this patient population. Study accrual is on target, with 261 out of a planned 300 metastatic tumor biopsies performed by August 2016. Paired biopsies have been completed in 42 patients, with paired genomic data before and after therapy obtained in 26 cases. Accrual is expected to be complete by December 2016.
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
Eur Urol Focus
DOI
EISSN
2405-4569
Publication Date
December 2016
Volume
2
Issue
5
Start / End Page
469 / 471
Location
Netherlands
Related Subject Headings
- 3202 Clinical sciences
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Aggarwal, R., Beer, T. M., Gleave, M., Stuart, J. M., Rettig, M., Evans, C. P., … Small, E. J. (2016). Targeting Adaptive Pathways in Metastatic Treatment-Resistant Prostate Cancer: Update on the Stand Up 2 Cancer/Prostate Cancer Foundation-Supported West Coast Prostate Cancer Dream Team. Eur Urol Focus, 2(5), 469–471. https://doi.org/10.1016/j.euf.2016.10.011
Aggarwal, Rahul, Tomasz M. Beer, Martin Gleave, Joshua M. Stuart, Matthew Rettig, Christopher P. Evans, Jack Youngren, et al. “Targeting Adaptive Pathways in Metastatic Treatment-Resistant Prostate Cancer: Update on the Stand Up 2 Cancer/Prostate Cancer Foundation-Supported West Coast Prostate Cancer Dream Team.” Eur Urol Focus 2, no. 5 (December 2016): 469–71. https://doi.org/10.1016/j.euf.2016.10.011.
Aggarwal R, Beer TM, Gleave M, Stuart JM, Rettig M, Evans CP, et al. Targeting Adaptive Pathways in Metastatic Treatment-Resistant Prostate Cancer: Update on the Stand Up 2 Cancer/Prostate Cancer Foundation-Supported West Coast Prostate Cancer Dream Team. Eur Urol Focus. 2016 Dec;2(5):469–71.
Aggarwal, Rahul, et al. “Targeting Adaptive Pathways in Metastatic Treatment-Resistant Prostate Cancer: Update on the Stand Up 2 Cancer/Prostate Cancer Foundation-Supported West Coast Prostate Cancer Dream Team.” Eur Urol Focus, vol. 2, no. 5, Dec. 2016, pp. 469–71. Pubmed, doi:10.1016/j.euf.2016.10.011.
Aggarwal R, Beer TM, Gleave M, Stuart JM, Rettig M, Evans CP, Youngren J, Alumkal JJ, Huang J, Thomas G, Witte O, Small EJ. Targeting Adaptive Pathways in Metastatic Treatment-Resistant Prostate Cancer: Update on the Stand Up 2 Cancer/Prostate Cancer Foundation-Supported West Coast Prostate Cancer Dream Team. Eur Urol Focus. 2016 Dec;2(5):469–471.
Published In
Eur Urol Focus
DOI
EISSN
2405-4569
Publication Date
December 2016
Volume
2
Issue
5
Start / End Page
469 / 471
Location
Netherlands
Related Subject Headings
- 3202 Clinical sciences
- 1103 Clinical Sciences